With the broad S&P 500 US stock index (SPX) closing the end of the third quarter up by almost 21% on the year to date, the rise of just over 9% in the NASDQ Biotech Index (NBI) over the same period seemed paltry. The recent protectionist specter of the BIOSECURE Act may have been unrelated to the biotech sector sitting out the last-minute stock market surge. (Also see "BIOSECURE Act: Potential Supply Chain Hits And Pharma’s Path Ahead" - Pink Sheet, 26 September, 2024.)
Stock Watch: Quarter-End Jockeying At Amgen And Regeneron
Skirmishes In More Than One Therapeutic Area In An Action-Packed Week
As broad stock markets finished the third quarter of 2024 on a high, two large biotech companies battled on more than one front. Despite both announcing positive news in the last week of the quarter, neither seemed to be a clear winner over that period.
More from Stock Watch
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
• By
Two pharmaceutical companies reporting bumper sales in the hot areas of diabetes and obesity may have helped a thaw in sector sentiment.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.